5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Alfonso CatalanoMario Romano

Abstract

5-lipoxygenase (5-LO) promotes cancer cell proliferation and survival by unclear mechanisms. Here, we show that 5-LO expression and activity were induced by genotoxic agents in a p53-independent manner and antagonized p53- or genotoxic drug-induced apoptosis in a variety of cancer cells. 5-LO inhibited p53-governed transactivation of the pro-apoptotic genes bax and pig3 but not of p21(WAF1/CIP1) or mdm2. This may be explained by 5-LO capability to inhibit the binding of p53 to promyelocytic leukemia protein (PML) and p53 subnuclear relocalization into PML-nuclear bodies in response to genotoxic stress. Interestingly, 5-LO activity appears to be involved in nuclear retention and inactivation of wild-type p53 in malignant mesothelioma cells. In these cells, genetic or pharmacological inhibition of 5-LO enabled suppression of in vitro tumorigenicity by low doses of chemotherapeutic drugs. Together, these results uncover novel functions of 5-LO and contribute to the understanding of 5-LO involvement in tumor progression. Moreover, they provide a rationale to the therapeutic use of 5-LO inhibitors to enhance cancer chemosensitivity in selected tumors.

References

Aug 1, 1995·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·E J GoetzlW L Smith
Feb 7, 1997·Cell·S Nagata
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·M E McCurrachS W Lowe
Oct 9, 1998·Genes & Development·A J Giaccia, M B Kastan
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·J Ghosh, C E Myers
May 26, 1999·The Journal of Pathology·C Prives, P A Hall
Aug 3, 1999·The Journal of Clinical Investigation·F BunzB Vogelstein
Feb 15, 2000·American Journal of Respiratory and Critical Care Medicine·M Peters-Golden, T G Brock
Nov 18, 2000·The EMBO Journal·V FogalG Del Sal
Dec 15, 2000·Cell·K H Vousden
Mar 30, 2001·The Journal of Biological Chemistry·C H LiuT Hla
Aug 21, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I AvisJ L Mulshine
Nov 2, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·M RomanoA Procopio
Jan 10, 2002·Nature Cell Biology·Gabriella D'OraziSilvia Soddu
Feb 8, 2002·Cell·Paolo Salomoni, Pier Paolo Pandolfi
Sep 11, 2002·Proceedings of the National Academy of Sciences of the United States of America·Karin Muller-DeckerGerhard Furstenberger
Nov 5, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mario Romano, Joan Claria
May 26, 2004·Critical Reviews in Oncology/hematology·Alfonso CatalanoAntonio Procopio

❮ Previous
Next ❯

Citations

Dec 24, 2004·The EMBO Journal·Alfonso CatalanoAntonio Procopio
Apr 25, 2009·The Journal of Biological Chemistry·Wenying JianIan A Blair
Sep 2, 2005·Proceedings of the National Academy of Sciences of the United States of America·Oliver WerzDieter Steinhilber
Aug 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Marija RakonjacOlof Rådmark
Jan 17, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Zaid H MaayahAyman O S El-Kadi
Jun 20, 2007·Trends in Biochemical Sciences·Olof RådmarkBengt Samuelsson
Nov 13, 2008·Journal of Veterinary Pharmacology and Therapeutics·L GoodmanS Budsberg
Nov 2, 2011·New Directions for Youth Development·Mat D Duerden, Ann Gillard
May 26, 2010·Journal of Internal Medicine·O Rådmark, B Samuelsson
Feb 15, 2005·Biochimica Et Biophysica Acta·Jung-Hyun KimKent L Erickson
Jul 14, 2006·Pharmacology & Therapeutics·Oliver Werz, Dieter Steinhilber
Jun 14, 2015·Biochimica Et Biophysica Acta·Bianca GilbertDieter Steinhilber
May 17, 2008·CNS Neuroscience & Therapeutics·Jun-Qing YangBai-Cheng He
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anatoly L MayburdJames L Mulshine
Nov 19, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stella UebbingDieter Steinhilber
Apr 25, 2020·Critical Reviews in Oncology/hematology·Tamkin AhmadzadaElham Hosseini-Beheshti
Jun 19, 2012·Clinical Epigenetics·Zhi-Yi GuoFang Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Mario RomanoA Procopio
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Mario Romano, Joan Claria
Biochemical and Biophysical Research Communications
Wei-Gang TongT E Adrian
© 2021 Meta ULC. All rights reserved